Peel Hunt reissued their buy rating on shares of PureTech Health (LON:PRTC) in a research note issued to investors on Thursday, ThisIsMoney.Co.Uk reports.
Other analysts have also recently issued reports about the company. Jefferies Financial Group upped their target price on PureTech Health from GBX 280 ($3.66) to GBX 340 ($4.44) and gave the company a buy rating in a report on Friday, July 5th. Liberum Capital upped their target price on Moneysupermarket.Com Group from GBX 520 ($6.79) and gave the company a buy rating in a report on Thursday.
Shares of PRTC stock opened at GBX 240 ($3.14) on Thursday. The firm has a 50 day moving average of GBX 223.52. PureTech Health has a one year low of GBX 135 ($1.76) and a one year high of GBX 239 ($3.12). The company has a market capitalization of $677.99 million and a PE ratio of -15.00. The company has a debt-to-equity ratio of 7.19, a current ratio of 0.98 and a quick ratio of 0.95.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Further Reading: What are retained earnings?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.